Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JRF101 + chemoradiation
- Development stage
- Unknown
- Lead developer
- Chengdu Jinruijiye Biotechnology
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Parenteral
01
Overview
JRF101 + chemoradiation is a combination therapy regimen being developed by Shenzhen Jinruijiye Biotechnology for the treatment of newly diagnosed glioblastoma (GBM). The novel component, JRF101, is a small molecule inhibitor delivered via a liposomal formulation that targets the transcription factor FOXM1 (Forkhead Box M1). FOXM1 is a key regulator of the cell cycle and DNA damage response, and its overexpression in GBM is associated with tumor progression, stemness, and resistance to standard therapies. By inhibiting FOXM1, JRF101 is designed to sensitize glioma cells to the cytotoxic effects of standard-of-care chemoradiation, which typically consists of temozolomide and radiotherapy. The program has received IND clearance and is entering Phase 1 clinical evaluation.
- Other names
- JRF101 combination with chemoradiationJRF-101 combination with chemoradiationJRF 101 combination with chemoradiation
02
Targets
FOXM1 (Forkhead box protein M1)DNA
Beyond the preview
Go deeper on JRF101 + chemoradiation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JRF101 + chemoradiation.